A strong device maker faces a cyber test
- Stryker is a global medical technology company serving more than 150 million patients a year.
- Q1 2026 sales grew only 2.6% to $6,020 million after a material cybersecurity incident disrupted operations.
- Adjusted operating margin fell 180 basis points to 21.1%, mainly from idle production time tied to the cyber event.
- The bull case depends on a fast Q2 and Q3 rebound and recapturing much of the roughly $375 million in deferred or lost Q1 sales.
- Finn's view is balanced: Stryker has strong franchises, but the recovery proof still matters.
The cyber hit now defines 2026
Stryker entered 2026 with healthy demand in its main markets. Then a cybersecurity incident on March 11, 2026 disrupted production and operations. Q1 sales grew 2.6% to $6,020 million, far below the high-single-digit pace investors had seen in the business. Adjusted operating margin fell 180 basis points to 21.1%.
The bull case is that this was a painful but temporary event. Hospitals still need joint replacements, surgical tools, emergency equipment, and stroke care products. Management kept full-year 2026 guidance, which points to confidence that some delayed sales can be recovered later in the year.
The bear case is that the cyber event showed real operating weakness. If customers could not get products on time, some may have shifted orders to competitors. If Q2 and Q3 do not show a clear sales and margin rebound, the one-time-event story gets much weaker.
The setup is not clean, but it is watchable. The next proof points are simple: faster sales growth, margin recovery, and clear comments on how much of the roughly $375 million in deferred or lost Q1 sales Stryker can win back.
Hospitals buy the tools and implants
Stryker makes money by selling medical devices and services to doctors, hospitals, and other healthcare facilities. Its products help in surgery, patient handling, emergency care, stroke treatment, joint replacement, trauma care, and spine-related procedures.
This is usually a steady kind of business. Many products are tied to needed care, not impulse spending. Stryker also benefits from a broad product bag and long sales relationships with hospitals.
The weak spot is execution. A hospital can like Stryker's products and still switch when supplies are late, prices rise, or regulators slow approvals. Q1 2026 showed that even a leading medical device company can lose sales when production systems stop working.
The product bag
Instruments
This includes surgical equipment and navigation systems used in operating rooms. It is part of the MedSurg and Neurotechnology segment.
Endoscopy
Endoscopy includes camera, scope, and communications systems that help doctors see and work inside the body during procedures.
Medical
This group includes patient handling, emergency medical equipment, and related hospital products. Demand is tied to daily hospital and emergency care needs.
Vascular
Vascular includes minimally invasive products for acute ischemic and hemorrhagic stroke and venous thromboembolism. The group grew after Stryker bought Inari Medical in 2025.
Hip and knee implants
Stryker sells implants used in joint replacement surgery. This is a core part of Orthopaedics and depends on procedure volume and surgeon preference.
Trauma, extremities, and spine therapies
These products support trauma, extremity, spinal injury, deformity, and degenerative care. The old Spinal Implants divestiture is nearly complete.
Ortho Tech and Mako
In Q1 2026, Stryker formed Ortho Tech by combining orthopaedic instruments with Mako and enabling technologies. The question is whether this makes robotic and tech-enabled orthopaedics easier for customers to adopt.
Two big engines
Segment mix is from Q1 2026 net sales of $6,020 million. MedSurg and Neurotechnology was larger, but both segments were affected by the cybersecurity disruption.
What could break the case
Cyber recovery falls short
High impact · Medium oddsThe March 2026 cybersecurity incident caused a material disruption to operations and hurt Q1 results. If Stryker cannot recover most delayed sales, full-year guidance may become too high. That would also raise questions about how strong customer loyalty really is.
Production costs stay higher
Medium impact · Medium oddsGross margin fell in Q1 2026 because manufacturing and supply chain costs rose, mainly from idle production time tied to the cyber event. Security repairs, plant restarts, and extra controls could add costs beyond one quarter. If that happens, the margin damage may last longer than investors expect.
Customers shift to rivals
High impact · Medium oddsMedical device markets are competitive. If hospitals or surgeons could not get Stryker products during the disruption, some orders may have moved to competitors. A small loss of trust can matter when products are used in repeat procedures.
Inari integration disappoints
Medium impact · Medium oddsStryker paid $4,745 million upfront, net of cash acquired, for Inari Medical in 2025. The deal expanded Vascular into venous thromboembolism treatment. The risk is that sales execution, product overlap, or integration costs reduce the expected benefit.
Regulation and pricing pressure
Medium impact · High oddsStryker sells globally and faces heavy medical device regulation, including EU MDR. Hospitals and governments also push to control healthcare costs. These forces can slow launches, add compliance spending, or pressure prices.
In one breath
What does Stryker actually sell?
Stryker sells medical technology used by hospitals and doctors. Its main areas include surgical equipment, endoscopy systems, emergency and patient handling products, vascular tools, joint implants, trauma products, and spine-related therapies.
Why did Stryker's Q1 2026 growth slow so much?
A material cybersecurity incident disrupted operations and production. Sales grew 2.6% in Q1 2026, and adjusted operating margin fell to 21.1% because idle production time raised costs.
Is the cybersecurity issue a one-time problem?
That is the key debate. The bull case says delayed sales can be recovered in Q2 and Q3. The bear case says some sales and trust may be permanently lost.
What is Ortho Tech?
Ortho Tech is a new business Stryker created in Q1 2026. It combines orthopaedic instruments with Mako and enabling technologies, which could help Stryker improve its tech-enabled orthopaedics offering.